
## **Product Data Sheet**

## PE/Cy7 anti-human IL-10

| Catalog # / Size:     | 3107100 / 100 tests<br>3107095 / 25 tests   |
|-----------------------|---|
| Clone:                | JES3-9D7  |
| Isotype:              | Rat IgG1, к   |
| Immunogen:            | COS - expressed, recombinant human<br>IL-10   |
| <b>Reactivity:</b>    | Human   |
| Preparation:          | The antibody was purified by affinity<br>chromatography, and conjugated with<br>PE/Cy7 under optimal conditions. The<br>solution is free of unconjugated PE/Cy7<br>and unconjugated antibody. |
| Formulation:          | Phosphate-buffered solution, pH 7.2,<br>containing 0.09% sodium azide and<br>0.2% (w/v) BSA (origin USA).   |
| <b>Concentration:</b> | Lot-specific  |




LPS-stimulated (overnight) human peripheral blood mononuclear cells surface stained with CD14 APC and intracellularly stained with JES3-9D7 PE/Cy7 (top data) or rat IgG1 isotype control PE/Cy7 (bottom data) (gated on monocyte population)

## **Applications:**

| Applications:         | Flow Cytometry   |
|-----------------------|--|
| Recommended<br>Usage: | Each lot of this antibody is quality<br>control tested by intracellular<br>immunofluorescent staining with flow<br>cytometric analysis. <b>Test size</b><br><b>products are transitioning from 20</b><br><b>microL to 5 microL per test</b> . Please<br>check your vial or your CoA to find the<br>suggested use of this reagent per<br>million cells in 100 microL staining<br>volume or per 100 microL of whole<br>blood. It is recommended that the<br>reagent be titrated for optimal<br>performance for each application. |

Application<br/>Notes:ELISA Capture<sup>1-5</sup> or ELISPOT<br/>Capture<sup>6</sup>: The purified JES3-9D7<br/>antibody is useful as the capture<br/>antibody in a sandwich ELISA, when<br/>used in conjunction with the biotinylated<br/>JES3-12G8 antibody (Cat. No. 501502)<br/>as the detecting antibody and<br/>recombinant human IL-10 (Cat. No.<br/>571009) as the standard. The LEAF™<br/>purified antibody is suggested for<br/>ELISPOT capture.<br/>Neutralization<sup>1-3,9</sup>: The LEAF™<br/>purified antibody (Endotoxin <0.1</td>

**Neutralization**<sup>1-3,9</sup>: The LEAF<sup>™</sup> purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of



| Application<br>References: | human IL-10 bioactivity (Cat. No.<br>501407). The JE53-9D7 antibody can<br>neutralize the bioactivity of natural or<br>recombinant IL-10.<br><b>Additional reported applications</b><br>(for the relevant formats)<br>include: immunohistochemical<br>staining <sup>12</sup> .<br><b>Note:</b> For testing human IL-10 in serum<br>or plasma, BioLegend's ELISA Max <sup>m</sup><br>Sets (Cat. No. 430601 to 430606) are<br>specially developed and recommended.<br>The JES3-9D7 antibody reacts with<br>human and viral interleukin-10 (IL-10).<br>1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)<br>2. Gotlieb W, et al. 1992. Cytokine 4:385. (ELISA Capture, Neut)<br>3. Yssel H, et al. 1992. J. Immunol. 149:2378. (ELISA Capture, Neut)<br>4. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.<br>(ELISA Capture)<br>5. Burdin N, et al. 1993. J. Exp. Med. 177:295. (ELISA Capture)<br>6. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit<br>6.19. (ELISPOT Capture)<br>7. Schaerli P, et al. 2000. J. Exp. Med. 192:1553.<br>8. Jason J, et al. 1998. J. Cin. Invest. 102:98. (Neut)<br>10. Stary G, et al. 2011. J. Immunol. 186:103. PubMed<br>11. Mason GM, et al. 2012. PNAS. PubMed<br>12. Smith DR, et al. 1994. Am. J. Pathol. 145:18. (IHC)<br>13. de Mason A, et al. 2015. Blood. 125:1830. PubMed |
|----------------------------|---|
| Description:               | IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.  |
| Antigen<br>References:     | 1. Fitzgerald K, <i>et al.</i> Eds. 2001. The Cytokine FactsBook. Academic Press San<br>Diego.<br>2. de Waal-Malefyt R, <i>et al.</i> 1992. <i>Curr. Opin. Immunol.</i> 4:314.<br>3. Howard M, <i>et al.</i> 1992. <i>Immunol. Today</i> . 13:198.  |